NASDAQ:TXG 10x Genomics (TXG) Stock Price, News & Analysis $15.10 -0.04 (-0.26%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About 10x Genomics Stock (NASDAQ:TXG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get 10x Genomics alerts:Sign Up Key Stats Today's Range$14.71▼$15.3050-Day Range$14.86▼$23.4952-Week Range$14.02▼$57.90Volume1.52 million shsAverage Volume1.70 million shsMarket Capitalization$1.80 billionP/E RatioN/ADividend YieldN/APrice Target$30.60Consensus RatingModerate Buy Company Overview10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Read More… Musk warns humanity: “Obsolete” (Ad)The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. 10x Genomics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks92nd Percentile Overall ScoreTXG MarketRank™: 10x Genomics scored higher than 92% of companies evaluated by MarketBeat, and ranked 90th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus Rating10x Genomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 7 buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst Coverage10x Genomics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about 10x Genomics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 10x Genomics are expected to grow in the coming year, from ($1.35) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 10x Genomics is -7.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 10x Genomics is -7.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio10x Genomics has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about 10x Genomics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.24% of the outstanding shares of 10x Genomics have been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in 10x Genomics has recently decreased by 4.74%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield10x Genomics does not currently pay a dividend.Dividend Growth10x Genomics does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.73 Percentage of Shares Shorted6.24% of the outstanding shares of 10x Genomics have been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in 10x Genomics has recently decreased by 4.74%, indicating that investor sentiment is improving. News and Social Media1.8 / 5News Sentiment0.31 News Sentiment10x Genomics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for 10x Genomics this week, compared to 5 articles on an average week.Search InterestOnly 7 people have searched for TXG on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat Follows14 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $316,794.00 in company stock.Percentage Held by Insiders10.03% of the stock of 10x Genomics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 10x Genomics' insider trading history. Receive TXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter. Email Address TXG Stock News HeadlinesPacBio includes Onso platform in 10x Genomics Compatible Partner ProgramOctober 23 at 2:28 AM | markets.businessinsider.comBarclays Lowers 10x Genomics (NASDAQ:TXG) Price Target to $21.00October 18, 2024 | americanbankingnews.com24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But here’s the thing: most people won’t be able to keep up with the pace of the market. That’s why I want to tell you about WaveBot – an automated trading tool created by my good friends Joel and Adam.October 24, 2024 | Crypto Swap Profits (Ad)10x Genomics, Inc. (NASDAQ:TXG) Given Average Rating of "Moderate Buy" by AnalystsOctober 17, 2024 | americanbankingnews.comStrategic Pricing and Market Expansion Drive 10x Genomics Buy RatingOctober 16, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Hold Rating on 10x Genomics (TXG)October 16, 2024 | markets.businessinsider.com10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium LaunchesOctober 15, 2024 | prnewswire.com10x Genomics, Inc. to Post Q3 2024 Earnings of ($0.31) Per Share, Leerink Partnrs Forecasts (NASDAQ:TXG)October 14, 2024 | americanbankingnews.comSee More Headlines TXG Stock Analysis - Frequently Asked Questions How have TXG shares performed this year? 10x Genomics' stock was trading at $55.96 at the beginning of 2024. Since then, TXG stock has decreased by 73.0% and is now trading at $15.10. View the best growth stocks for 2024 here. How were 10x Genomics' earnings last quarter? 10x Genomics, Inc. (NASDAQ:TXG) released its earnings results on Thursday, August, 8th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.15. The business earned $153.10 million during the quarter, compared to analyst estimates of $150.90 million. 10x Genomics had a negative net margin of 37.90% and a negative trailing twelve-month return on equity of 28.23%. When did 10x Genomics IPO? 10x Genomics (TXG) raised $297 million in an initial public offering on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager. Who are 10x Genomics' major shareholders? 10x Genomics' top institutional investors include Slow Capital Inc. (0.10%), Mirador Capital Partners LP (0.05%), Allspring Global Investments Holdings LLC (0.03%) and Lecap Asset Management Ltd. (0.03%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Mathai Mammen, Justin J Mcanear, James Wilbur, Sridhar Kosaraju and Bradford Crutchfield. View institutional ownership trends. How do I buy shares of 10x Genomics? Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of 10x Genomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that 10x Genomics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings8/08/2024Today10/24/2024Next Earnings (Confirmed)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:TXG CUSIPN/A CIK1770787 Webwww.10xgenomics.com Phone925-401-7300FaxN/AEmployees1,259Year FoundedN/APrice Target and Rating Average Stock Price Target$30.60 High Stock Price Target$60.00 Low Stock Price Target$16.00 Potential Upside/Downside+102.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-255,100,000.00 Net Margins-37.90% Pretax Margin-36.92% Return on Equity-28.23% Return on Assets-21.95% Debt Debt-to-Equity RatioN/A Current Ratio5.22 Quick Ratio4.42 Sales & Book Value Annual Sales$631.73 million Price / Sales2.85 Cash FlowN/A Price / Cash FlowN/A Book Value$6.22 per share Price / Book2.43Miscellaneous Outstanding Shares119,167,000Free Float108,406,000Market Cap$1.80 billion OptionableOptionable Beta1.85 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:TXG) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.